selected scholarly activity
-
chapters
-
journal articles
- Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Probable Alzheimer Patients. Alzheimer Disease and Associated Disorders. 36:269-271. 2022
- Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Stroke Patients. Journal of Stroke and Cerebrovascular Diseases. 29:104502-104502. 2020
- Stability, Activity, and Application of Topical Doxycycline Formulations in a Diabetic Wound Case Study.. Wounds. 31:49-54. 2019
- A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products. PLoS ONE. 13:e0196396-e0196396. 2018
- Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine. PLoS ONE. 13:e0194979-e0194979. 2018
- Penetration and efficacy of transdermal NSAIDs in a model of acute joint inflammation. Journal of Pain Research. Volume 11:2809-2819. 2018
- Synapsin II gene expression in the dorsolateral prefrontal cortex of brain specimens from patients with schizophrenia and bipolar disorder: effect of lifetime intake of antipsychotic drugs. Pharmacogenomics Journal. 14:63-69. 2014
- Dysregulation of novel catecholamine‐regulated protein 40 (CRP40) in Parkinson's disease patients. Movement Disorders. 28:1460-1461. 2013
- Human blood analysis reveals differences in gene expression of catecholamine-regulated protein 40 (CRP40) in schizophrenia. Schizophrenia Research. 143:203-206. 2013
- Knockdown of mortalin within the medial prefrontal cortex impairs normal sensorimotor gating. Synapse. 64:808-813. 2010
- Antipsychotic drug use is correlated with CRP40/mortalin mRNA expression in the dorsolateral prefrontal cortex of human postmortem brain specimens. Schizophrenia Research. 119:228-231. 2010
- Cloning, characterization, and functional studies of a human 40-kDa catecholamine-regulated protein: implications in central nervous system disorders. Cell Stress and Chaperones. 14:555-567. 2009
- Guanosine improves motor behavior, reduces apoptosis, and stimulates neurogenesis in rats with parkinsonism. Journal of Neuroscience Research. 87:617-625. 2009
- Differential modulation of a 40 kDa catecholamine regulated protein in the core and shell subcompartments of the nucleus accumbens following chronic quinpirole and haloperidol administration in the rat. Synapse. 61:835-842. 2007
- Translocation of AIF in the human and rat striatum following protracted haloperidol, but not clozapine treatment. Apoptosis : an international journal on programmed cell death. 11:663-672. 2006
- cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects. Pharmacogenomics Journal. 6:131-140. 2006
- Decreased expression of a 40-kDa catecholamine-regulated protein in the ventral striatum of schizophrenic brain specimens from the Stanley Foundation Neuropathology Consortium. Schizophrenia Research. 74:111-119. 2005
- Asymmetric modulation of a catecholamine‐regulated protein in the rat brain, following quinpirole administration. Synapse. 49:261-269. 2003
- Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia. Peptides. 24:313-319. 2003
- Modulation of a 40-kDa catecholamine-regulated protein following d-amphetamine treatment in discrete brain regions. European Journal of Pharmacology. 453:13-19. 2002
- Expression of the 40 kDa catecholamine regulated protein in the normal and injured rat retina. Journal of Chemical Neuroanatomy. 24:41-48. 2002